Jacek Gronwald1, Karen Glass2, Barry Rosen3, Beth Karlan4, Nadine Tung5, Susan L Neuhausen6, Pal Moller7, Peter Ainsworth8, Ping Sun9, Steven A Narod10, Jan Lubinski1, Joanne Kotsopoulos9. 1. International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. 2. CReATe Fertility Centre, Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada. 4. Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, West Hollywood, California. 5. Beth Israel Deaconess Medical Center, Boston, Massachusetts. 6. Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California. 7. Research Group Inherited Cancer, Department of Medical, Genetics, Oslo University Hospital, Oslo, Norway. 8. London Regional Cancer Program, London, Ontario, Canada. 9. Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada. 10. Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada. Electronic address: steven.narod@wchospital.ca.
Abstract
OBJECTIVE: To evaluate the relationship between use of fertility medication (i.e., selective estrogen receptor [ER] modulator, gonadotropin, or other) or infertility treatment (i.e., IVF or IUI) and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. DESIGN: A matched case-control study of 941 pairs of BRCA1 or BRCA2 mutation carriers with and without a diagnosis of ovarian cancer. SETTING: Genetic clinics. PATIENT(S): Detailed information regarding treatment of infertility was collected from a routinely administered questionnaire. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Conditional logistic regression was used to estimate odds ratios and 95% confidence intervals associated with fertility treatment. RESULT(S): There was no significant relationship between the use of any fertility medication or IVF treatment (odds ratio, 0.66; 95% confidence interval 0.18-2.33) and the subsequent risk of ovarian cancer. CONCLUSION(S): Our findings suggest that treatment for infertility does not significantly increase the risk of ovarian cancer among women with a BRCA mutation.
OBJECTIVE: To evaluate the relationship between use of fertility medication (i.e., selective estrogen receptor [ER] modulator, gonadotropin, or other) or infertility treatment (i.e., IVF or IUI) and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. DESIGN: A matched case-control study of 941 pairs of BRCA1 or BRCA2 mutation carriers with and without a diagnosis of ovarian cancer. SETTING: Genetic clinics. PATIENT(S): Detailed information regarding treatment of infertility was collected from a routinely administered questionnaire. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Conditional logistic regression was used to estimate odds ratios and 95% confidence intervals associated with fertility treatment. RESULT(S): There was no significant relationship between the use of any fertility medication or IVF treatment (odds ratio, 0.66; 95% confidence interval 0.18-2.33) and the subsequent risk of ovarian cancer. CONCLUSION(S): Our findings suggest that treatment for infertility does not significantly increase the risk of ovarian cancer among women with a BRCA mutation.